BioNTech SE (NASDAQ:BNTX) Shares Bought by Capital International Ltd. CA

Capital International Ltd. CA grew its position in shares of BioNTech SE (NASDAQ:BNTX) by 8.6% during the first quarter, HoldingsChannel reports. The firm owned 22,874 shares of the company’s stock after buying an additional 1,808 shares during the period. Capital International Ltd. CA’s holdings in BioNTech were worth $2,110,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in BNTX. GAMMA Investing LLC lifted its stake in shares of BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after acquiring an additional 150 shares in the last quarter. CWM LLC raised its position in shares of BioNTech by 657.6% in the 4th quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after purchasing an additional 217 shares in the last quarter. Frazier Financial Advisors LLC purchased a new position in shares of BioNTech during the 4th quarter valued at approximately $30,000. First Horizon Advisors Inc. purchased a new position in shares of BioNTech during the 4th quarter valued at approximately $38,000. Finally, Covestor Ltd grew its position in shares of BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after buying an additional 133 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on BNTX shares. Evercore ISI assumed coverage on shares of BioNTech in a report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price target on the stock. BMO Capital Markets cut their target price on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 7th. HC Wainwright reiterated a “buy” rating and issued a $113.00 price target on shares of BioNTech in a research note on Wednesday, June 26th. Finally, TD Cowen boosted their price objective on BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $111.70.

BioNTech Stock Performance

BNTX traded up $1.26 on Friday, hitting $85.94. 264,744 shares of the company’s stock were exchanged, compared to its average volume of 691,346. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average of $89.32 and a two-hundred day moving average of $91.59. BioNTech SE has a twelve month low of $78.02 and a twelve month high of $125.83. The firm has a market cap of $20.43 billion, a PE ratio of 171.88 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). The company had revenue of $203.69 million for the quarter, compared to analyst estimates of $589.96 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. On average, research analysts anticipate that BioNTech SE will post -2 earnings per share for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.